{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-169805","form_type":"8-K","ticker":"CALC","cik":"0001534133","company_name":"CalciMedica, Inc.","filed_at":"2024-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.878254+00:00","generated_at":"2026-06-01T00:59:49.332693+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"CalciMedica announces positive Phase 2b CARPO topline data for Auxora in acute pancreatitis","bullets":["Trial enrolled 216 patients; primary endpoint met with up to 43.6% relative risk reduction in time to solid food tolerance vs placebo in hyper-inflamed subgroup.","Auxora showed statistically significant dose response: severe organ failure reduced by up to 61.7% in medium dose vs placebo.","High dose patients had 0% hospital stays >21 days vs 5.7% placebo; combined high/medium dose showed 84.3% relative risk reduction.","Auxora well-tolerated: only 1 drug-related treatment-emergent serious adverse event across all dose groups; no related deaths in high dose.","Company plans End-of-Phase 2 meeting with FDA and intends to present additional CT data at a medical meeting later in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-169805","json":"https://secwatch.observer/filing/0001193125-24-169805.json","markdown":"https://secwatch.observer/filing/0001193125-24-169805.md","text":"https://secwatch.observer/filing/0001193125-24-169805.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534133/000119312524169805/0001193125-24-169805-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534133/000119312524169805/d124614d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T00:59:49.332693+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}